This trial is evaluating whether Atezolizumab will improve 2 primary outcomes and 3 secondary outcomes in patients with Melanoma. Measurement will happen over the course of 63 months.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. Atezolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Melanoma affects about one in 5000 US Caucasians a year, most commonly on the head (58%), followed by body (23%) and melanoma of skin (19%). The average age at diagnosis was 59 years." - Anonymous Online Contributor
"Melanomas may produce a mass or tender node(s) in the skin. The most reliable signs are the appearance of the lesion in childhood and its appearance prior to the age of five. When a patient first visits a doctor, physicians or other medical personnel should pay attention to what the patient says. A doctor can determine if a patient will be diagnosed with melanoma by observing what the patient says to a health professional. For example, an elderly person may report signs such as dryness on palms of hands or on soles of feet, and bluish veining on the back of the arms and legs, and the skin might feel cracked, thickened, or scaly." - Anonymous Online Contributor
"Melanoma is a type of cancer that can arise in several locations within the body as a form of malignancy that is caused by a faulty genome and is often resistant to a variety of treatments. The prognosis for melanomas is strongly dependent on location and tumour thickness, and there is evidence that melanomas of the scalp have a more favourable prognosis than melanomas of the head and neck, including the scalp, eyes, lips, trunk, hands, feet and genitalia." - Anonymous Online Contributor
"It is not well understood the complex process of cellular transformation from normal to malignant transformation. While the process of wound healing does not appear essential in the development of melanoma, the process of neovascularization is suggested as a major step in tumor growth. It is suggested that modulation of this process by either chemotherapeutic or natural agents may be of benefit in the treatment of melanoma." - Anonymous Online Contributor
"Melanoma is frequently diagnosed at an advanced stage. Treatment options include surgery, radiation therapy, or chemotherapy, with or without targeted or immunotherapy. Survival of patients with melanoma is generally poor." - Anonymous Online Contributor
"This prospective phase II study highlights the need for improved melanoma pathology, earlier diagnosis, and more effective and improved therapeutic regimens to enable cure. Results from a recent paper also highlight the need to have greater understanding of the risk factors for early-stage, metastatic melanoma and the role of the primary tumor in determining response to therapy." - Anonymous Online Contributor
"Recent findings revealed that UV exposure and genetics are the major causes of melanoma. However, a significant percentage of melanoma cases are not caused by UV exposure. This suggests the existence of some factors that promote the tumor growth. Also, there is a good correlation between the occurrence of familial melanoma and UV exposure, indicating that familial melanoma might be caused either by a specific genetic predisposition to the disease or by a defect in regulatory genes controlling tumor formation." - Anonymous Online Contributor
"Clinical trials for melanoma would be most beneficial to patients with Stage 1 disease<10mm, or who are older than 70 years, as well as those with histologic or clinical features of ulceration, or ulcerated or thick melanomas. They may be less beneficial for patients with ulcerated melanomas<4.1 mm, or thin melanomas<1.5 mm, or ulcerated or thick melanomas>4.1 mm. Therefore, clinicians should consider these variables when planning clinical trials aimed at improving survival." - Anonymous Online Contributor
"Recent literature highlights new developments in melanoma treatment, detection and prognosis. This article highlights current advances to the understanding of melanoma's development, progression and drug resistance, and aims to provide an update." - Anonymous Online Contributor
"Since we can compare the data, there is a great deal of variation, partly because of differences in the age of individuals tested. Median age for melanoma patients was 68.23 years. Mean age was 64.9, and mean age at diagnosis was 55.7. In our study cohort, over half of melanoma patients were male. The age of melanoma patients differed significantly between genders, with the mean age being younger for male patients. In comparison, the median age of male patients was greater. In both male and female populations, the average age of death was younger. We would therefore look to see whether any correlation exists between the patient's survival versus the overall average age of mortality for the age at diagnosis or age at death." - Anonymous Online Contributor
"Atezolizumab is a humanized monoclonal antibody that binds to programmed cell death-1 and is marketed as a treatment in metastatic melanoma. A phase III trial demonstrated superiority of atezolizumab versus observation. A phase III trial of adjuvant atezolizumab in stage III melanoma did not demonstrate improved survival. In February 2011, atezolizumab was approved for use in the US and Europe. There are a number of side effects, mainly neurological. These include\nneuropathic pain, sensory neuropathy, aseptic meningitis, cerebellar syndrome, and reversible hearing loss. In August, 2012, the U.S." - Anonymous Online Contributor
"Currently, no new medications are effective, but they are being researched for their potential therapeutic effects. The identification of growth-suppressing factors in melanoma tumors leads researchers to the identification of new targets for the treatment of melanoma. Targeted genetic therapy for melanoma may eventually be the most promising therapy, in part, because some of the key genes involved in the development and progression of melanoma are known. In addition, targeted therapy is more likely to succeed in melanomas than in other common cancers because melanoma is a cancer that is inherently metastatic and often more advanced before patients are diagnosed." - Anonymous Online Contributor